Avatrombopag in Patients With End-stage Liver Disease and Thrombocytopenia

  • End date
    Dec 31, 2022
  • participants needed
  • sponsor
    Tongji Hospital
Updated on 16 June 2021
platelet count
liver disease


End stage liver disease is prone to thrombocytopenia. This study is a multi-center, randomized, prospective, randomized controlled Phase IV Clinical trial to discuss the Efficacy and Safety of Avatrombopag in Patients with End-stage Liver Disease and Thrombocytopenia.


End stage liver disease is prone to thrombocytopenia. This study aims to discuss the Efficacy and Safety of Avatrombopag in Patients with End-stage Liver Disease and Thrombocytopenia in a multicenter, prospective, randomized controlled trial. The patients were divided into one of the groups according to if receiving avatrombopag. Avatrombopag was taken to maintain platelet count 50~10010^9/L. Starting dose is recommended according to the patient's baseline platelet count level. Routine treatment was taken in the Control group and Interventional group. This trial will take about 2 to 2.5 years from the first participant signing an informed consent form (ICF) until all study-related telephone follow-ups or visits end.

Condition Thrombocytopenia, Hepatic Insufficiency, Thrombocytopenia and Thrombocytopenia Prevention, Hepatic Failure, Liver Failure, Decompensated Cirrhosis
Treatment Standard Medical Treatment, Avatrombopag
Clinical Study IdentifierNCT04906083
SponsorTongji Hospital
Last Modified on16 June 2021


Yes No Not Sure

Inclusion Criteria

Men and women greater than or equal to 18 years of age
Baseline platelet count <5010^9/L
End-stage liver disease, including acute-on-chronic liver failure, acute decompensation of liver cirrhosis, chronic liver failure
Women of childbearing potential must agree to use a highly effective method of contraception from the beginning of Baseline Visit until the end of treatment (includes implantable contraception, injectable contraception, hormonal combination contraception [including vaginal rings], intra-uterine devices or vasectomy). The barrier contraception with or without spermicide alone, double barrier contraception and oral contraceptives are inadequate
Subject is able to understand the study and willing to follow the protocol and sign informed consent voluntarily before Baseline Visit
Subject meet the criteria according to the opinion of the researchers

Exclusion Criteria

Subject has a history of arterial or venous thrombosis within the previous 6 months of baseline
Known portal vein blood flow velocity rate <10 cm/second or previous occurrence of a portal vein thrombosis within 6 months of Baseline
Known any history of primary blood (e.g, immune thrombocytopenia, myelodysplastic syndrome, aplastic anemia)
Subject has a known medical history of genetic prothrombotic syndromes (e.g, Factor V Leiden prothrombin G20210A, antithrombin III (AT III) deficiency)
Subject has a recent history (within the previous 6 months) of significant cardiovascular diseases (e.g., exacerbation of congestive heart failure, arrhythmias known to increase the risk of thromboembolic events [e.g. atrial fibrillation], coronary or peripheral artery stent placement or angioplasty, and coronary or peripheral artery bypass grafting)
Female subjects who are lactating or pregnant at the Baseline Visit (as documented by a positive serum beta-human chorionic gonadotropin [-hCG] test with a minimum sensitivity of 25 IU/L or equivalent units of -hCG) or are planning to become pregnant during the study
The subject has a hypersensitivity to Avatrombopag or any of its excipients
Subjects with drug-induced thrombocytopenia
Subjects whose Life expectation 6 months
Subject with a current malignancy
Subjects with HIV infection
At screening, active infection was not effectively controlled by systemic antibiotic therapy
The Investigator believe that any accompanying medical history may affect the safety of the subjects to complete the study
The Investigator believe that there are any other factors that are not suitable for inclusion or affect participation or completion of the study
Subject is enrolled in another clinical study with any investigational drug or device within previous 30 days of the Baseline Visit, but are allowed to participate in observational studies
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note